4.8 Article

Antioxidants Accelerate Lung Cancer Progression in Mice

Journal

SCIENCE TRANSLATIONAL MEDICINE
Volume 6, Issue 221, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3007653

Keywords

-

Funding

  1. European Research Council
  2. Goran Gustafsson Foundation
  3. Swedish Children's Cancer Fund
  4. BioCARE-a National Strategic Research Program at the University of Gothenburg
  5. Ingabritt and Arne Lundberg's Research Foundation
  6. Swedish Cancer Society
  7. Swedish Research Council
  8. Vastra Gotalandsregionen
  9. Heart and Lung Foundation
  10. Polysackaridforskning AB
  11. Assar Gabrielsson Foundation
  12. Magnus Bergvall
  13. Ake Wiberg
  14. Lars Hierta Memorial Foundations

Ask authors/readers for more resources

Antioxidants are widely used to protect cells from damage induced by reactive oxygen species (ROS). The concept that antioxidants can help fight cancer is deeply rooted in the general population, promoted by the food supplement industry, and supported by some scientific studies. However, clinical trials have reported inconsistent results. We show that supplementing the diet with the antioxidants N-acetylcysteine (NAC) and vitamin E markedly increases tumor progression and reduces survival in mouse models of B-RAF- and K-RAS-induced lung cancer. RNA sequencing revealed that NAC and vitamin E, which are structurally unrelated, produce highly coordinated changes in tumor transcriptome profiles, dominated by reduced expression of endogenous antioxidant genes. NAC and vitamin E increase tumor cell proliferation by reducing ROS, DNA damage, and p53 expression in mouse and human lung tumor cells. Inactivation of p53 increases tumor growth to a similar degree as antioxidants and abolishes the antioxidant effect. Thus, antioxidants accelerate tumor growth by disrupting the ROS-p53 axis. Because somatic mutations in p53 occur late in tumor progression, antioxidants may accelerate the growth of early tumors or precancerous lesions in high-risk populations such as smokers and patients with chronic obstructive pulmonary disease who receive NAC to relieve mucus production.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available